Celldex Therapeutics (CLDX) vs. Concert Pharmaceuticals (CNCE) Financial Contrast
Celldex Therapeutics (NASDAQ: CLDX) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
52.6% of Celldex Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Concert Pharmaceuticals shares are held by institutional investors. 4.1% of Celldex Therapeutics shares are held by insiders. Comparatively, 10.1% of Concert Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Celldex Therapeutics and Concert Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Celldex Therapeutics and Concert Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Celldex Therapeutics||$6.79 million||58.28||-$128.53 million||($1.01)||-2.88|
|Concert Pharmaceuticals||$170,000.00||3,194.50||-$50.72 million||$3.75||6.36|
Concert Pharmaceuticals has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations for Celldex Therapeutics and Concert Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celldex Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 157.73%. Concert Pharmaceuticals has a consensus target price of $24.75, indicating a potential upside of 3.77%. Given Celldex Therapeutics’ higher possible upside, equities analysts plainly believe Celldex Therapeutics is more favorable than Concert Pharmaceuticals.
Volatility & Risk
Celldex Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Concert Pharmaceuticals beats Celldex Therapeutics on 7 of the 12 factors compared between the two stocks.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company’s product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.